SOFIVA Genomics, a leading brand in genetic testing, released its February earnings report, announcing revenue of NTD $34.531 million. Cumulatively, SOFIVA has reached NTD $78.534 million this year, a 1.78%-growth compared to the same period last year. The Company expects to launch its new product – SOFIVA Endometrial Cancer Genetic Subtypes – in April to continue expanding its market size in precision medicine in oncology.

First-ever Genotyping Test for Endometrial Cancer – Expanding Dominance in Precision Medicine

In response to the downward shift in the onset age of endometrial cancer, SOFIVA is developing Taiwan's first-ever genotyping test for endometrial cancer based on the Cancer Genome Atlas (TCGA) to protect women's health better. Chia-Cheng Hong, General Manager of SOFIVA, asserted, “The current classification system for endometrial cancer system is subjective and discordant, making it easy to underestimate malignancy. SOFIVA Endometrial Cancer Genetic Subtypes can classify endometrial cancer in greater detail. It will not only help physicians determine patient status and prognosis but also assist them in tailoring more effective treatment plans.”

At present, the main approaches for classifying endometrial cancer patients are histopathological morphology, FIGO stage, tumor grade, and imaging. Patients also undergo risk assessments to determine subsequent course of treatment. SOFIVA Endometrial Cancer Genetic Subtypes can categorize endometrial cancer into four types according to the latest NCCN guidelines, which can help physicians identify high-risk patients or patients with a poor prognosis.

Targeted Cancer Treatment – 270% Hike in Cancer Detection Revenue

Issues pertaining to early detection, risk management, and prevention are becoming increasingly valued as precision medicine advances. SOFIVA incorporated liquid tumor biopsy technology into cancer detection and launched the SOFIVA Cancer Scan for healthy people and SOFIVA Cancer Monitor and SOFIVA NSCLC EGFR Mutation Test for cancer patients. Since the launch of these services in 2018, business revenue in these areas has grown by 270%. Chia-Cheng Hong, General Manager of SOFIVA, emphasized, “Liquid tumor biopsy has become a mainstream test among clinical physicians. It can be used to not only monitor changes in real-time but also to detect relapse or new mutations early. Clinical physicians can also use the biopsy reports to formulate custom drug regimens and treatment strategies.”